Morning home blood pressure may be a significant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1

Hypertension Research

Volumn 32, Issue 9, 2009, Pages 770-774

  Tanaka, Yasushi ^a   Daida, Hiroyuki ^b   Imai, Yutaka ^c   Miyauchi, Katsumi ^b   Sato, Yasukazu ^d   Hiwatari, Masao ^e   Kitagawa, Akira ^f   Kishimoto, Junji ^g   Yamazaki, Tsutomu ^h   Kawamori, Ryuzo ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Medical Corporation of Kouhoukai   (Japan)

^e International University of Health and Welfare   (Japan)

^f INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANDESARTAN; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; LOSARTAN; OLMESARTAN; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE MARKER; DRUG MEGADOSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOME MONITORING; HUMAN; HYPERTENSION; JAPANESE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORNING HOME BLOOD PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PULSE WAVE; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WORKPLACE;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 70249105014     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.96     Document Type: Article

References (18)

1. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27 (Suppl 1): S79-S83.
2. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HAW, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-1769.
3. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. Br Med J 2000; 321: 412-419.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317: 703-713.
5. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27(Suppl 1): S65-S67.
6. Aihara A, Imai Y, Sekino M, Kato J, Ito S, Ohkubo T, Tsuji I, Satoh H, Hisamichi S, Nagai K. Discrepancy between screening blood pressure and ambulatory blood pressure: A community-based study in Ohasama. Hypertens Res 1998; 21: 127-136.
7. Vollmer WM, Appel LJ, Svetkey LP, Moore TJ, Vogt TM, Conlin PR, Proschan M, Harsha D. DASH Collaborative Research Group, comparing office-based and ambulatory blood pressure monitoring in clinical trials. J Hum Hypertens 2005; 19: 77-82.
8. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, Ito S, Satoh H, Hisamichi S. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: A population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971-975.
9. Gorostidi M, Sobrino J, Segura J, Sierra C, de la Sierra A, Hernández del Rey R, Vinyoles E, Galcerán JM, López-Eady MD, Marín R, Banegas JR, Sarría A, Coca A, Ruilope LM. Spanish Society of Hypertension ABPM Registry Investigators, ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: A cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens 2007; 25: 977-983.
10. Kawamori R, Daida H, Tanaka Y, Miyauchi K, Kitagawa A, Hayashi D, Kishimoto J, Ikeda S, Imai Y, Yamazaki T. Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). BMC Cardiovasc Disord 2006; 6: 39.
11. Yano Y, Katsuki A, Gabazza EC, Ito K, Fujii M, Furuta M, Tuchihashi K, Goto H, Nakatani K, Hori Y, Sumida Y, Adachi Y. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 1999; 84: 2353-2356.
12. Nagai T, Imamura M, Inukai T, Mori M. Brain natriuretic polypeptide in type 2 NIDDM patients with albuminuria. J Med 2001; 32: 169-180.
13. Igarashi M, Jimbu Y, Hirata A, Tominaga M. Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. Endocr J 2005; 52: 353-362.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretics: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
15. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE study group, cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.
16. Kamoi K, Miyakoshi M, Soda S, Kaneko S, Nakagawa O. Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care 2002; 25: 2218-2223.
17. Nielsen FS, Gaede P, Vedel P, Pedersen O, Parving HH. White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care 1997; 20: 859-863.
18. Leitão CB, Canani LH, Kramer CK, Boza JC, Pinotti AF, Gross JL. Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care 2007; 30: 1255-1260.